Considerations on nosology for HIV-associated neurocognitive disorders: it is time to update?
- 1 Downloads
The prognosis and the clinical manifestations of HIV infection have changed with the introduction of the potent combination antiretroviral therapy (cART); however, up to 50% of patients meet research criteria for “HIV-associated neurocognitive disorders” (HAND) according with current nosology. The majority of patients affected by HAND, especially in cohorts with suppressed plasma viremia, showed an Asymptomatic Neurocognitive Impairment (ANI), without any functional impairment. After more than 10 years from the introduction of the current so-called “Frascati criteria”, this mini-review aimed to address the emerging limitations in current diagnosis procedures.
We discussed the most relevant literature on HAND prevalence, etiology, and diagnosis.
We addressed three main emerging issues: (1) the unclear clinical relevance of ANI entity; (2) the evidences that Frascati criteria could produce a significant overestimation of HAND; (3) the need to better identify patients with a higher risk to develop HAND requiring routine neuropsychological examinations.
Frascati criteria should be updated to better respond to the present characteristics of HIV + cohorts and to help clinicians in their cognitive and global management.
KeywordsHIV HIV-associated neurocognitive disorders Nosology Risk factors
Compliance with ethical standards
Conflict of interest
The author declares that they have no competing interests.
- 3.Janssen RS, Cornblath DR, Epstein LG, Foa RP, McArthur JC, Price RW, et al. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778–85.CrossRefGoogle Scholar
- 16.Ciccarelli N, Limiti S, Fabbiani M, Baldonero E, Milanini B, Lamonica S, et al. Verbal list learning and memory profiles in HIV-infected adults, Alzheimer’s disease, and Parkinson’s disease: an evaluation of the “cortical hypothesis” of NeuroAIDS. Appl Neuropsychol Adult. 2017;24:410–9. https://doi.org/10.1080/23279095.2016.1189424.CrossRefPubMedGoogle Scholar
- 29.Ciccarelli N, Fabbiani M, Colafigli M, Trecarichi EM, Silveri MC, Cauda R, et al. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther. 2013;18:153–60. https://doi.org/10.3851/IMP2560.CrossRefPubMedGoogle Scholar
- 31.Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, et al. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility. Antivir Ther. 2015;20:441–7. https://doi.org/10.3851/IMP2926.CrossRefPubMedGoogle Scholar
- 33.Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26:1765–74. https://doi.org/10.1097/QAD.0b013e328355e6b2.CrossRefPubMedGoogle Scholar
- 35.Valero IP, Letendre S, Ellis R, Deutsch R, Franklin D, Clifford D, et al. Prevalence and risk factors for HIV CSF Viral Escape: results from the CHARTER and HNRP cohorts. J Int AIDS Soc. 2012;15:18189.Google Scholar
- 40.McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699–714.Google Scholar
- 46.Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135–40. https://doi.org/10.1016/j.ebiom.2015.11.036.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med. 2013;14:136–44. https://doi.org/10.1111/j.1468-1293.2012.01044.x.CrossRefGoogle Scholar
- 63.Clay PG, Yuet WC, Moecklinghoff CH, Duchesne I, Tronczyński KL, Shah S, Shao D. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15:17. https://doi.org/10.1186/s12981-018-0204-0.CrossRefPubMedPubMedCentralGoogle Scholar